Cargando…

Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials

BACKGROUND: Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and to identify subpopulations exhibiting the gr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Yu Mi, Cho, Yun Kyung, Lee, Jiwoo, Lee, Seung Eun, Lee, Woo Je, Park, Joong-Yeol, Kim, Ye-Jee, Jung, Chang Hee, Nauck, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712219/ https://www.ncbi.nlm.nih.gov/pubmed/30604598 http://dx.doi.org/10.4093/dmj.2018.0070

Ejemplares similares

Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: He, Liyun, et al.
Publicado: (2020)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
por: Mahapatra, Manoj Kumar, et al.
Publicado: (2022)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist
por: Cho, Yun Kyung, et al.
Publicado: (2023)

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
por: Song, Rui, et al.
Publicado: (2022)

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
por: Uccellatore, Annachiara, et al.
Publicado: (2015)

Predictive value of the Framingham steatosis index for cardiovascular risk: a nationwide population-based cohort study
por: Cho, Yun Kyung, et al.
Publicado: (2023)

Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
por: Tanaka, Atsushi, et al.
Publicado: (2018)

The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
por: Kim, Gwang Sil, et al.
Publicado: (2019)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis
por: Lee, Yeong-Min, et al.
Publicado: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Triglyceride–Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study
por: Cho, Yun Kyung, et al.
Publicado: (2022)

Hypertension-Mediated Organ Damage and Long-term Cardiovascular Outcomes in Asian Hypertensive Patients without Prior Cardiovascular Disease
por: Oh, Jung Sun, et al.
Publicado: (2020)

History of the Asian Society of Cardiovascular Imaging
por: Lee, Wen-Jeng, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
por: Monami, Matteo, et al.
Publicado: (2011)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
por: Lin, Yuan, et al.
Publicado: (2023)

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
por: Tan, Xi, et al.
Publicado: (2023)

The time‐varying cardiovascular benefits of glucagon‐like peptide‐1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials
por: Deo, Salil V., et al.
Publicado: (2022)

Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes
por: Cho, Yun Kyung, et al.
Publicado: (2019)

Metabolic health is a determining factor for incident colorectal cancer in the obese population: A nationwide population‐based cohort study
por: Cho, Yun Kyung, et al.
Publicado: (2020)

Differential Effect of Metabolic Health and Obesity on Incident Heart Failure: A Nationwide Population-Based Cohort Study
por: Kim, Hwi Seung, et al.
Publicado: (2021)

The risk of Alzheimer’s disease according to dynamic changes in metabolic health and obesity: a nationwide population-based cohort study
por: Cho, Yun Kyung, et al.
Publicado: (2021)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
por: Kim, Hwi Seung, et al.
Publicado: (2021)

Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results
por: Pantalone, Kevin M., et al.
Publicado: (2020)

Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction
por: Trevisan, Marco, et al.
Publicado: (2020)

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
por: Sawami, Kosuke, et al.
Publicado: (2022)

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
por: Garber, Alan J.
Publicado: (2011)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

Direct cardiovascular effects of glucagon like peptide-1
por: Sheikh, Asfandyar
Publicado: (2013)

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
por: Choe, Hun Jee, et al.
Publicado: (2021)

Response: Triglyceride-Glucose Index Predicts Cardiovascular Outcome in Metabolically Unhealthy Obese Population: A Nationwide Population-Based Cohort Study (J Obes Metab Syndr 2022;31:178-86)
por: Cho, Yun Kyung, et al.
Publicado: (2023)

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons
por: Dalsgaard, Niels B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_20opoh3sr24acshvdv0qmeblf4